ArticleClinicoEconomics and outcomes research : CEOR2019

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient.

Marie Fournier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.